# CURRENT_STATE_NC001_v3_POST_ROUNDTRIP_BRIDGE

## Governing state

- Architecture v1.1 remains frozen.
- Canonical predecessor: runtime v0.2.15.3.
- Runtime SHA-256: exact canonical match.
- SQLite SHA-256: exact canonical match.
- MVP_LINGUISTICO_001 v0.1/v0.2: inspected read-only; no legacy similarity path reused for generation.
- COR001 role: `ANALYSIS_TARGET_ONLY`.

## Generator

`Generator_v0.1 = HARDENED`

`GENERATOR_RUNTIME_DEPENDENCY = MATERIALIZED_INPUTS_WITH_VERIFIED_CANONICAL_ADAPTER`

The generator is still materialized-input based. It is not converted into a general runtime-dependent generator. For novel generation only, an injected bridge now provides a round-trip gate composed from canonical runtime components plus existing NC001 schemas.

`ROUNDTRIP_ANALYSIS_MODE = COMPOSED_CANONICAL_RUNTIME_WITH_EXISTING_NC001_SCHEMAS`

This is not equivalent to claiming that v0.2.15.3 exposes a general canonical analyzer orchestrator; it still does not.

## Generation state

- C01:
  - zero-novelty source-attested assembly remains available;
  - first `LICENSED_NOVEL_RECOMBINATION` now exists under the round-trip bridge:
    - `Ma' beedabe`
    - `GL-NC001-C01-V01-C3SG-ALREADY-NOVEL-001`
    - surface origin: `PROJECT_GENERATED`
    - whole-surface evidence: none.
- C02: zero-novelty only.
- C03: `MISSING_QUESTION_PATTERN`.
- C04: `INTERROGATIVE_DOMAIN_SCOPE_MISMATCH`; frozen scope unchanged, TIME not added.
- C05: `MISSING_NOUN_POSSESSION_LICENSE_SET`.
- C06: `DEPENDENT_POTENTIAL_OUT_OF_SCOPE`; do not resolve within NC001.

## Safety invariants still active

- no paradigm inference;
- no self-licensing;
- no near-match / similarity generation;
- no strip-tone decision path;
- no PDLMA->surface generation;
- no derived-evidence laundering;
- `PROJECT_GENERATED != SOURCE_ATTESTATION`;
- novel generation requires explicit orthographic policy IDs and compatible round-trip;
- no use of COR001 for benchmark/regression/gold/rule discovery/approval.

## Immediate next step

Do not generalize yet. Treat the first novel license as a closed proof of mechanism. The next step should be a small post-license review of whether the bridge contract is sufficiently independent and generalizable before attempting a second novel recombination.
